Intermittent (versus continuous) androgen deprivation therapy (ADT) seems to be associated with an increase in the incidence of ischaemic and thrombotic events, according to a new study. Hershman et al. linked Medicare claims data with data from a multicentre trial comparing intermittent with continuous ADT. They found that the 10-year cumulative incidence of ischaemic and thrombotic events was 24% in the continuous ADT group and 33% in the intermittent ADT group. No differences were seen between groups in bone, endocrine or cognitive events.